Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/31910
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJain, Bhawana-
dc.contributor.authorJain, Amita-
dc.contributor.authorPrakash, Om-
dc.contributor.authorSingh, Ajay Kr-
dc.contributor.authorDangi, Tanushree-
dc.contributor.authorSingh, Mastan-
dc.contributor.authorSingh, KP-
dc.date.accessioned2015-08-05T11:22:53Z-
dc.date.available2015-08-05T11:22:53Z-
dc.date.issued2015-08-
dc.identifier.issn0975-1009 (Online); 0019-5189 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/31910-
dc.description514-521en_US
dc.description.abstractThe genomic variability of Influenza A virus (IAV) makes it difficult for the existing vaccines or anti-influenza drugs to control. The siRNA targeting viral gene induces RNAi mechanism in the host and silent the gene by cleaving mRNA. In this study, we developed an universal siRNA and validated its efficiency in vitro. The siRNA was designed rationally, targeting the most conserved region (delineated with the help of multiple sequence alignment) of M gene of IAV strains. Three level screening method was adopted, and the most efficient one was selected on the basis of its unique position in the conserved region. The siRNA efficacy was confirmed in vitro with the Madin Darby Canine Kidney (MDCK) cell line for IAV propagation using two clinical isolates i.e., Influenza A/H3N2 and Influenza A/pdmH1N1. Of the total 168 strains worldwide and 33 strains from India, 97 bp long (position 137-233) conserved region was identified. The longest ORF of matrix gene was targeted by the selected siRNA, which showed 73.6% inhibition in replication of Influenza A/pdmH1N1 and 62.1% inhibition in replication of Influenza A/H3N2 at 48 h post infection on MDCK cell line. This study provides a basis for the development of siRNA which can be used as universal anti-IAV therapeutic agent.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJEB Vol.53(08) [August 2015]en_US
dc.subjectAnti-IAV siRNAen_US
dc.subjectH1N1en_US
dc.subjectH3N2en_US
dc.subjectIAVen_US
dc.subjectMultiple sequence alignmenten_US
dc.subjectMDCK cell lineen_US
dc.subjectsiRNA efficacyen_US
dc.titleIn vitro validation of self designed “universal human Influenza A siRNA”en_US
dc.typeArticleen_US
Appears in Collections:IJEB Vol.53(08) [August 2015]

Files in This Item:
File Description SizeFormat 
IJEB 53(8) 514-521.pdf256.94 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.